GlassScriptPhysician profile
Susan Wilson
NPI 1396757811
$10,430.30
in general payments reported to CMS, 2019-2025
70 companies · $3,055 in 2025
The $3,055 reported for 2025 was more than what 86% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,484 · 2022: $1,629 · 2023: $1,827 · 2024: $2,435 · 2025: $3,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,120 · Long Term Medical Supply Or Device Loan: $833 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,120.25 |
| Long Term Medical Supply Or Device Loan | $833.30 |
| Education | $363.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,021.49 | 2023-2025 | Piqray, Kisqali |
| Incyte Corporation | $622.26 | 2021-2025 | Jakafi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $619.37 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $488.69 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $440.12 | 2021-2025 | Opdualag, Krazati, Augtyro |
| Eisai INC. | $413.91 | 2021-2025 | |
| Astellas Pharma US INC | $383.76 | 2021-2025 | Padcev, Xtandi, Xospata |
| Daiichi Sankyo INC. | $373.14 | 2021-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $362.59 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $333.58 | 2021-2025 | Fruzaqla, Alunbrig, Hyqvia |
| Emd Serono, INC. | $291.46 | 2024-2025 | |
| Celgene Corporation | $289.82 | 2021-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $289.27 | 2021-2025 | |
| Pfizer INC. | $268.02 | 2022-2025 | |
| Glaxosmithkline, LLC. | $254.86 | 2022-2025 | Jemperli, Ojjaara, Zejula |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $246.81 | 2022-2025 | Erleada, Rybrevant, Tecvayli |
| Sobi, INC | $236.03 | 2022-2025 | |
| Seagen INC. | $215.79 | 2021-2023 | Padcev |
| Amgen INC. | $208.91 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Stemline Therapeutics INC. | $162.83 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $151.32 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Boston Scientific Corporation | $144.95 | 2024 | |
| Myriad Genetic Laboratories, INC. | $143.52 | 2023 | Myrisk |
| Kite Pharma, INC. | $140.84 | 2022-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $115.31 | 2022-2025 | |
| Tempus Ai, INC | $114.24 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $112.90 | 2022-2025 | Venclexta, Phesgo |
| Acrotech Biopharma INC. | $111.69 | 2022-2025 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $109.08 | 2025 | |
| Pharmacosmos Therapeutics INC. | $106.90 | 2021-2025 | Monoferric |
| Genmab U.S., INC. | $98.79 | 2023-2025 | Tivdak, Epkinly |
| Karyopharm Therapeutics INC. | $95.38 | 2021-2025 | Xpovio |
| Puma Biotechnology, INC. | $94.28 | 2021-2025 | |
| Genzyme Corporation | $89.02 | 2022-2025 | |
| Coherus Oncology, INC. | $88.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $85.14 | 2021-2022 | |
| Mirati Therapeutics, INC. | $80.98 | 2023-2024 | Krazati |
| Array Biopharma INC | $75.06 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Tersera Therapeutics LLC | $73.50 | 2024-2025 | Zoladex |
| Abbvie INC. | $60.64 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $56.72 | 2023 | Clonoseq |
| Taiho Oncology, INC. | $56.45 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.54 | 2022-2025 | Lynozyfic |
| Spectrum Pharmaceuticals INC. | $43.91 | 2024 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.91 | 2021-2023 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $36.19 | 2024-2025 | Qinlock, Romvimza |
| Azurity Pharmaceuticals, INC. | $34.99 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $32.55 | 2023 | Sylvant |
| Kyowa Kirin, INC. | $32.09 | 2024 | Poteligeo |
| Springworks Therapeutics, INC. | $31.29 | 2024-2025 | Ogsiveo |
| Sumitomo Pharma America, INC. | $30.79 | 2023 | Orgovyx |
| Beigene USA, INC. | $30.69 | 2022-2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $29.66 | 2021 | |
| Morphosys, US INC. | $29.10 | 2023 | Monjuvi |
| Cti Biopharma Corp. | $28.40 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $22.81 | 2025 | |
| Beone Medicines USA, INC. | $20.26 | 2025 | Tevimbra |
| Helsinn Therapeutics (U.S.), INC. | $19.95 | 2022 | |
| Secura Bio, INC. | $18.30 | 2022 | |
| Pharmaessentia USA Corporation | $18.08 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $17.90 | 2024 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $17.67 | 2021 | |
| Geron Corporation | $16.34 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $16.34 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.00 | 2021 | |
| Epizyme, INC. | $14.89 | 2021 | |
| Legend Biotech USA INC. | $14.72 | 2025 | Carvykti |
| Immunogen, INC. | $14.11 | 2023 | Elahere |
| Foundation Medicine, INC. | $14.05 | 2022 | |
| Iovance Biotherapeutics, INC. | $13.35 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.